GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at

GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection